News
FDA hands another rejection to Replimune's melanoma therapy
Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.
News
Roche places a $1bn bet on C4T degrader-antibody conjugates
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
Oncology
LSX2026: Addressing adult eye cancer, with Roi Raz
Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
News
Syneron raises $150m for macrocyclics, and other financings
Our round-up of recent biotech venture capital financings includes nine-figure rounds for Syneron, Stipple Bio, and Sidewinder.
Oncology
From preclinical toxicology to clinical safety: The path for...
Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
